Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment

Journal of Toxicology and Environmental Health - Part B: Critical Reviews

Volumn 6, Issue 1, 2003, Pages 1-40

  Dixit, Rakesh ^a   Riviere, Jim ^b   Krishnan, Kannan ^c   Andersen, Melvin E ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; DICHLOROMETHANE; DIOXIN; ORGANIC COMPOUND; RETINOIC ACID; VINYL CHLORIDE; XENOBIOTIC AGENT;

ALGORITHM; ANIMAL EXPERIMENT; CONCENTRATION RESPONSE; CONTINUING EDUCATION; DOSE RESPONSE; DRUG ABSORPTION; ENVIRONMENTAL EXPOSURE; HUMAN; INHALATION; LIVER TOXICITY; MATHEMATICAL MODEL; METHODOLOGY; NONHUMAN; ORGAN WEIGHT; PRACTICE GUIDELINE; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; SAFETY; TIME SERIES ANALYSIS; TISSUE DISTRIBUTION; TOXICOKINETICS;

ANIMALS; HAZARDOUS SUBSTANCES; HUMANS; MODELS, CHEMICAL; RISK ASSESSMENT; TOXICOLOGY; XENOBIOTICS;

ANIMALIA;

EID: 0037216771     PISSN: 10937404     EISSN: None     Source Type: Journal    
DOI: 10.1080/10937400306479     Document Type: Review

References (79)

1. Abelson, P. H. 1990. Testing of carcinogens with rodents. Science 249:1387.
2. Ames, B. N., and Gold, L. S. 1990. Chemical carcinogenesis: Too many rodent carcinogens. Proc. Natl. Acad. Sci. USA 87:7772-7776.
3. Andersen, M. E. 1991. Physiological modelling of organic compounds. Ann. Occup. Med. 35:305-321.
4. Andersen, M. E., Clewell, H. J. III, Gargas, M. L., Smith, F. A., and Reitz, R. H. 1987. Physiologically-based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87:185-205.
5. Andersen, M. E., Mills, J. J., Gargas, M. L., Kedderis, L., Birnbaum, L. S., Neubert, D., and Greenlee, W. F. 1993. Modeling receptor-mediated processes with dioxin: Implications for pharmacokinetics and risk assessment. J. Risk Anal., 13:25-36.
6. Andersen, M. E., Birnbaum, L. S., Barton, H. A., and Eklund, C. 1997. Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multi-compartment geometric model of hepatic zonation. Toxicol. Appl. Pharmacol. 144:145-155.
7. Andersen, M. E., Sarangapani, R., Frederick, C. B., and Kimbell, J. S. 1999. Dosimetric Adjustment factors for methylmethacrylate derived from a steady-state analysis of a physiologically based clearance-extraction model. Inhal. Toxicol. 11:899-926.
8. Andersen, M. E., Sarangapani, R., Gentry, P. R., Clewell, H. J. III, Covington, T. R., and Frederick, C. B. 2000. Application of a hybrid CFD-PBPK nasal dosimetry in an inhalation risk assessment: An example with acrylic acid. Toxicol. Sci. 57:312-325.
9. Arms, A. D., and Travis, C. C. 1998. Physiological Parameters in Pharmacokinetic Modelling. EPA/600/6-88/004, 1-1-7.16. Washington, DC: Office of Health and Environmental Assessment, U.S. EPA.
10. Bachmann, K., Pardoe, D., and White, D. 1996. Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect. 104:400-407.
11. Benet, L. Z., and Sceiner, L. B., 1985. In The Pharmacological Basis of Therapeutics, eds. A. G. Gilman, L. S. Goodman, T. W. Rall, and F. Murad, 7th ed. New York: Macmillan.
12. Bogdanffy, M. S., Sarangapani, R., Plowchalk, D. R., Jarabek, A., and Andersen, M. E. 1999. A biologically-based risk assessment for vinyl acetate-induced cancer and non-cancer inhalation toxicity. Toxicol. Sci. 51:19-35.
13. Bourne, D. W. A. 1995. Mathematical Modeling of Pharmacokinetic Data. Lancaster, PA: Technomic.
14. Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., and Beliles, R. P. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13:407-484.
15. Caines, P. E. 1988. Linear Stochastic Systems. New York: Wiley and Sons.
16. Caldwell, J. 1992. Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. Toxicol. Lett. 64/65:651-659.
17. Chemical Industry Institute of Toxicology. 1999. Formaldehyde: Hazard Characterization and Dose-response Assessment for Carcinogenicity by the Route on Inhalation. Research Triangle Park, NC: CIIT.
18. Chen, C. W., and Blancato, J. N. 1989. Incorporation of biological information in cancer risk assessment: Example - Vinyl chloride. Cell Biol. Toxicol. 5:417-444.
19. Clewell, H. J. III, and Andersen, M. E. 1985. Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health 1:111-131.
20. Clewell, H. J. III, and Andersen, M. E. 1987. Dose, species and route extrapolation using physiologically based pharmacokinetic models. Drinking Water Health 8:159-182.
21. Clewell, H. J., Gentry, P. R., Gearhart, J. M., Allen, B. C., and Andersen, M. E. 1995. Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: Examples with vinyl chloride and trichloroethylene. Chemosphere 31:2561-2578.
22. Clewell, H. J. III, Andersen, M. E., Wills, R. J. Wills, and Latriano, L. 1997. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J. Am. Acad. Dermatol. 36:S77-S85.
23. Clewell, H. J., Gentry, R., Gearhart, J. M., Allen, B. C., and Andersen, M. E. 2001. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Science of the Total Environment. 274:37-66.
24. Contrera, J. F., Jacobs, A. C., Prasanna, H. R., Mehta, M., Schmidt, W. J., and De George, J. 1995. A systemic exposure based alternative to the maximum tolerated dose for carcinogenicity studies of human therapeutics. J. Am. Coll. Toxicol. 14:1-10.
25. Counts, J., and Goodman, J. 1995. Principles underlying dose selection for, and extrapolation from the carcinogen bioassay: Dose influences mechanism. Regul. Toxicol. Pharmacol. 21:418-421.
26. Davies, B., and Morris, T. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
27. DeGeorge, J. 1995. Food and Drug Administration's viewpoint on toxicokinetics. The view from review. Toxicol. Pathology 23:220-225.
28. Effect of dose and time in a long-term, low dose carcinogenicity study. J. Environ Pathol. Toxicol. 8:17-34.
29. Environmental Protection Agency (EPA), Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry, EPA/600/8-90/066F (Office of Health and Environmental Assessment, Washington, D.C., 1994).
30. Federal Register. 1996. Part II Environmental Protection Agency. 40 CFR 799. Proposed test rule for hazardous air pollutants; proposed rule. Fed. Reg., June 26, 1996. 33177-3320.
31. Feron, V. J., Hendriksen, C. F. M., Speek, A. J. 1981. Lifespan oral toxicity study of vinyl chloride in rats. Food Cosmet. Toxicol. 19:317-333.
32. Fox, A. J., and Collier, P. F. 1977. Mortality experience of workers exposure to vinyl chloride monomer in the manufacture of polyvinyl chloride in Great Britain. Br. J. Ind. Med. 34:1-10.
33. Frederick, C., Bush, M. L., Subramaniam, R. P., Black, K. A., Finch, L., Kimbell, J. S., Morgan, K. T., Subramaniam, R. P., Morris, J. B., and Ultman, J. S. 1998. Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways. Toxicol. Appl. Pharmacol. 152:211-231.
34. Gabrielsson, J., and Weiner, D. 1997. Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications, 2nd Ed. Stockholm: Apotekarsocieteten.
35. Gelman, A., Bois, F., and Jiang, J. 1996. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc. 91:1400-1412.
36. Gerlowski, L. E., and Jain, R. K. 1983. Physiologically based pharmacokinetic modeling: Principles and applications. J. Pharm. Sci. 72:1103-1127.
37. Gibaldi, M., and Perrier, D. 1982. Pharmacokinetics, 2nd Ed. New York: Marcel Dekker.
38. Haddad, S., Pelekis, M., and Krishnan, K. 1996. A methodology for solving physiologically based pharmacokinetic models without the use of simulation software. Toxicol. Lett. 85:113-126.
39. Haddad, S., Withey, J. R., Laparé, S., Law, F. C. P., and Krishnan, K. 1998. Physiologically-based pharmacokinetic modeling of pyrene in the rat. Environ. Toxicol. Pharmacol. 5:245-255.
40. Haseman, J. K., and Lockhart, A. 1994. The relationship between use of maximum tolerated dose and study sensitivity for detecting rodent carcinogenicity. Fundam. Appl. Toxicol. 22:382-391.
41. Health Canada, 1993. Canadian Environmental Protection Act. Priority Substances List Assessment Report. Dichloromethane. Ottawa, Canada: Canada Communication Group.
42. ICH. 1995a. Guidelines on assessment of systemic exposure in toxicity studies. Fed. Reg. 60(40):11264-11268.
43. ICH. 1995b. Guidelines on dose selection for carcinogenicity studies of pharmaceuticals. Fed. Reg. 60(40):11278-11281.
44. ICH. 1995c. Guidelines on repeated dose tissue distribution studies. Fed. Reg. 60(40):11274-11275.
45. International Life Sciences Institute. 1977. An Evaluation of EPA's Proposed Guidelines for Carcinogen Risk Assessment Using Chloroform and Dichloroacetic Acid as Case Studies: Report of an Expert Panel. Washington, DC: International Life Sciences Institute, Health and Environmental Sciences Institute.
46. Iwatsubo, T., Suzuki, H., and Sugiyama, Y. 1997. Prediction of species differences (rat, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J. Pharmacol. Exp. Ther. 283:462-469.
47. Jones, R. W., Smith, D. M., and Thomas, P. G. 1988. A mortality study of vinyl chloride monomer workers employed in the United Kingdom in 1940B1974. Scand. J. Work Environ. Health 14:153-160.
48. Kedderis, G. L., and Held, S. D. 1996. Prediction of furan pharmacokinetics from hepatocyte studies: Comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol. Appl. Pharmacol. 140:124-130.
49. Kohn, M. C., Lucier, G. W., Clark, G. C., Sewall, C., Tritscher, A., and Portier, C. J. 1993. A mechanistic model of the effects of dioxin on gene expression in the rat liver. Toxicol. Appl. Pharmacol. 120:138-154.
50. Krishnan, K., and Andersen, M. E. 2001. Physiologically based pharmacokinetic modeling in toxicology. In Principles and Methods of Toxicology, ed. A. W. Hayes, pp. 193-241. Philadelphia: Taylor & Francis.
51. Krishnan, K., Gargas, M. L., and Andersen, M. E. 1993. In vitro toxicology and risk assessment. Alt. Methods Toxicol. 9:185-203.
52. Leung, H. W. 1991. Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J. Toxicol. Environ. Health 32:247-267.
53. Littlefield, N. A., Farmer, J. H., and Gaylor, D. W. 1979. Effect of dose and time in a long-term, low dose carcinogenicity study. J. Environ. Pathol. Toxicol. 8:17-34.
54. Lipscomb, J. C., Fisher, J. W., Confer, P. D., and Byczkowski, J. Z. 1998. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol. Appl. Pharmacol. 152:376-387.
55. Mahmood, I., and Balian. 1999. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin. Pharmacokinet. 36:1-11.
56. Maltoni, C., Lefemine, G., Ciliberti, A., Cott, G., and Caretti, D. 1981. Carcinogenicity bioassay of vinyl chloride monomer: A model of risk assessment on an experimental basis. Environ. Health Perspect. 41:3-29.
57. Maltoni, C., Lefemine, G., Ciliberti, A., Cotti, G., and Caretti, D. 1984. Experimental research on vinyl chloride carcinogenesis. In Archives of research on Industrial Carcinogenesis, vol. 2, eds. C. Maltoni and M. A. Mehlman, pp. Princeton, NJ: Princeton Scientific.
58. McConnell, E. E. 1989. The maximum tolerated dose: The debate. J. Am. Coll. Toxicol. 8:1115-1120.
59. Morris, J. B., Hassett, D. N., and Blanchard, K. T. 1993. A physiologically based pharmacokinetic model for nasal uptake and metabolism of nonreactive vapors. Toxicol. Appl. Pharmacol. 123:120-129.
60. Monro, A. 1994. Drug toxicokinetics: Scope and limitations that arise from species differences in pharmacodynamic and carcinogenesis response. J. Pharmacokinet. Biopharm. 12:41-57.
61. Mortensen, B., and Nilsen, O. G. 1998. Allometric species comparison of toluene and n-hexane metabolism: Prediction of hepatic clearance in man from experiments with rodent liver S9 in a head space vial equilibration system. Pharmacol. Toxicol. 82:183-188.
62. National Research Council. 1986. Drinking Water and Health, vol. 6, chap. 6. Washington, DC: National Academy Press.
63. Occupational Safety and Health Administration. 1997. Occupational exposure to methylene chloride; final rule. Fed. Reg. 62(7):1493-1619.
64. Plowchalk, D. R., Andersen, M. E., and Bogdanffy, M. S. 1997. Physiologically-based modeling of vinyl acetate uptake, metabolism and intracellular pH changes in the rat nasal cavity. Toxicol. Appl. Pharmacol. 142:386-400.
65. Poulin, P., and Krishnan, K. 1996. Molecular structure-based prediction of the partition coefficients of organic chemicals for physiological pharmacokinetic models. Toxicol. Methods 6:117-137.
66. Poulin, P., and Krishnan, K. 1999. Molecular structure-based prediction of the toxicokinetics of inhaled vapors in humans. Int. J. Toxicol. 18:7-18.
67. Reitz, R. H., Gargas, M. L., Andersen, M. E., Provan, W. M., and Green, T. L. 1996. Predicting cancer risk from vinyl chloride exposure with a physiologically-based pharmacokinetic model. Toxicol. Appl. Pharmacol. 137:253-267.
68. Renwick, A. G., 1994. Toxicokinetics-pharmacokinetics. In Priniciples and Methods of Toxicology, 3rd Edit., ed. A. W. Hayes, pp. 101-147. New York: Raven Press.
69. Riviere, J. E. 1999. Comparative Pharmacokinetics: Principles, Techniques and Applications. Ames: Iowa State University Press.
70. Rowland, M., and Tozer, T. N. 1995. Clinical Pharmacokinetics: Concepts and Applications, 3rd Ed. Philadelphia: Lea and Febiger.
71. Simonato, L., L'Abbe, K. A., Andersen, A., Belli, S., Comba, P., Engholm, G., Ferro, G., Hagmar, L., Langard, S., Lundberg, I., Pirastu, R., Thomas, P., Winkelmann, R., and Saracci, R. 1991. A collaborative study of cancer incidence and mortality among vinyl chloride workers. Scand. J. Work Environ. Health 17:159-169.
72. Smith, D. A. 1990. Design of toxicokinetic studies. Xenobiotica 20:1187-1199.
73. Tritscher, A. M., Goldstein, J. A., Portier, C. J., McCoy, Z., Clark, G. C., and Lucier, G. W. 1992. Dose-response relationships for chronic exposure to 2,3,7,8-tetrchlorodibenzo-p-dioxin in a rat tumor promotion model: Quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Cancer Res. 52:3436-3442.
74. U.S. Environmental Protection Agency. 1994. Methods for Derivation of Inhaled Reference Concentrations and Application of Inhalation Dosimetry. EPA/600/8-90/066F. Washington, DC: Office of Research and Development.
75. U.S. Environmental Protection Agency. 1996. Proposed Guidelines for Carcinogen Risk Assessment. EPA/600/P-92/003C. Washington, DC: Office of Research and Development.
76. U.S. Environmental Protection Agency. 2000a. Toxicological Review of Vinyl Chloride. Appendices A-D. EPA/635R-00/004.
77. U.S. Environmental Protection Agency. 2000b. Exposure and human health reassessment of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Part II. In Health Assessment for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and Related Compounds., chap. 8, Dose-response Modeling for 2,3,7,8-TCDD. NCEA-1-0835. May. Science Advisory Board Review Draft.
78. Voisin, E., Ruthsatz, M., Collins, J. M., and Hoyle, P. C., 1990. Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development. Regul. Toxicol. Pharmacol. 12:107-116.
79. Welling, P. G., and de la Igelsia, F. A., eds. 1993. Drug Toxicokinetics. New York: Marcel Dekker.